ENGN logo

ENGN enGene Holdings Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$2.41
+0.13 (+5.70%)

Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is …

Market Cap: $161.51Mwww.engene.com

Price

No data yet.

Social Signal Score

68
5d
—
30d
70
1 mentions
—
60d
70
3 mentions
—
90d
64
6 mentions
—
news: 6

Analyst Ratings

9 analysts
Buyconsensus
Strong Buy 0Buy 5Hold 3Sell 1Strong Sell 0
Avg price target$4.33+79.7%
Low $3Median $4High $6
Current Consensus

Revenue

$0.00
$0.00
Dec 2021Jul 2026

Analyst Estimates

FY2025
$-2.10
$-2.15–$-2.04
7 analysts
FY2026
$-1.82
$-1.89–$-1.73
5 analysts
FY2027
$-1.58
$-1.92–$-1.37
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Ronald H. W. Cooper
Sector
Healthcare
Industry
Biotechnology
Employees
82
Beta
-0.28
Country
CA
Piotroski score
0 / 9 (Weak)
Altman Z-score
-1.06
www.engene.com